WHO Drug Information Vol. 17, No. 3, 2003
(2003; 85 pages) View the PDF document
Table of Contents
Open this folder and view contentsRational Use of Drugs
Open this folder and view contentsSafety and Efficacy Issues
Open this folder and view contentsIndividual Drugs
Open this folder and view contentsAspects of Quality Assurance
Open this folder and view contentsConsultation Document
Open this folder and view contentsRegulatory and Safety Action
Open this folder and view contentsRegulatory Challenges
Close this folderATC/DDD Classification
View the documentFinal List
View the documentTemporary list
View the documentProposed International Nonproprietary Names: List 89
View the documentAnnex 1 - Procedure for the selection of recommended international nonproprietary names for pharmaceutical substances*
View the documentAnnex 2 - General principles for guidance in devising international nonproprietary names for pharmaceutical substances*
View the documentAnnexe 1 - Procédure a suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques
View the documentAnnexe 2 - Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques*
View the documentAnexo 1 - Procedimiento de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas
View the documentAnexo 2 - Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas*
 

Final List

The following final anatomical therapeutic chemical (ATC) classifications and defined daily doses (DDDs) were agreed at a meeting of the WHO International Working Group for Drug Statistics Methodology which took place on 23-24 October 2002. They came into force on 1 March 2003 and are included in the January 2004 issue of the ATC index. The inclusion of a substance in the lists does not imply any recommendation of use in medicine or pharmacy. Comments or objections to the decisions from the meeting should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology, e-mail: whocc@nmd.no.

ATC level

INN/Common name

ATC code

New ATC level codes (other than 5th level):

 

Direct thrombin inhibitors

B01AE

Other anterior pituitary hormones and analogues

H01AX

Prostaglandin analogues

S01EE

New ATC 5th level codes:

   
 

adalimumab

L04AA17

 

adefovir dipivoxil

J05AF08

 

afelimomab

L04AA16

 

alefacept

L04AA15

 

aluminium diacetate

D10AX05

 

argatroban

B01AE03

 

benidipine

C08CA15

 

beraprost

B01AC19

 

bimatoprost

S01EE03

 

carbon dioxide

V03AN02

 

ciclesonide

R03BA08

 

combinations

D06AX30

 

docosanol

D06BB11

 

eflornithine

D11AX16

 

eprosartan and diuretics

C09DA02

 

ertapenem

J01DH03

 

etilevodopa and decarboxylase inhibitor

N04BA06

 

etoricoxib

M01AH05

 

everolimus

L04AA18

 

fasudil

C04AX32

 

frovatriptan

N02CC07

 

glutaral

D08AX09

 

gusperimus

L04AA19

 

helium

V03AN03

 

insulin aspart

A10AD05

 

lanthanum carbonate

V03AE03

 

levodopa, decarboxylase inhibitor and COMT inhibitor

N04BA03

 

levofloxacin

S01AX19

 

lofexidine

N07BC04

 

lovastatin, combinations

C10AA52

 

melagatran

B01AE04

 

melevodopa

N04BA04

 

melevodopa and decarboxylase inhibitor

N04BA05

 

methotrexate

L04AX03

 

moxonidine and diuretics

C02LC05

 

nitrogen

V03AN04

 

oxygen

V03AN01

 

pegvisomant

H01AX01

 

pimecrolimus

D11AX15

 

polygeline

B05AA10

 

rifampicin, pyrazinamide and isoniazid

J04AM05

 

rifampicin, pyrazinamide, ethambutol and isoniazid

J04AM06

 

rifapentin

J04AB05

 

telmisartan and diuretics

C09DA07

 

travoprost

S01EE04

ATC codes changes:

   

Previous:

desirudin

B01AX02

New:

desirudin

B01AE01

Previous:

latanoprost

S01EX03

New:

latanoprost

S01EE01

Previous:

lepirudin

B01AX03

New:

lepirudin

B01AE02

Previous:

unoprostone

S01EX04

New:

unoprostone

S01EE02

ATC name changes:

   

Previous:

ethambutol, combinations

 

New:

ethambutol and isoniazid

J04AM03

Previous:

rifampicin, combinations

 

New:

rifampicin and isoniazid

J04AM02

Previous:

somatropin and analogues

 

New:

somatropin and somatropin agonists

H01AC

Previous:

streptomycin, combinations

 

New:

streptomycin and isoniazid

J04AM01

Previous:

thioacetazone, combinations

 

New:

thioacetazone and isoniazid

J04AM04

New DDDs:

INN/common name

DDD

Unit

Adm.R

ATC code

anakinra

0.1

g

P

L04AA14

bosentan

0.25

g

O

C02KX01

dutasteride

0.5

mg

O

G04CB02

ertapenem

1

g

P

J01DH03

etoricoxib

60

mg

O

M01AH05

fentanyl

0.6

mg

SL

N02AB03

ferric oxide dextran complex

0.1

g Fe3+

P

B03AC06

fondaparinux

2.5

mg

P

B01AX05

frovatriptan

2.5

mg

O

N02CC07

fulvestrant

8.3

mg

P

L02BA03

gatifloxacin

0.4

g

O, P

J01MA16

glatiramer acetate

20

mg

P

L03AX13

lofexidine

1.4

mg

O

N07BC04

memantine

20

mg

O

N06DX01

miglustat

0.3

g

O

A16AX06

mometasone

0.4

mg

Inhal.powder

R03BA07

octreotide

0.7

mg

P

H01CB02

peginterferon alfa-2a

26

mcg

P

L03AB11

risperidone

1.8

mg

P depot

N05AX08

tenecteplase

40

mg

P

B01AD11

tenofovir disoproxil

0.245

g

O

J05AF07

tiotropium bromide

18

mcg

Inhal.powder

R03BB04

voriconazole

0.4

g

O, P

J02AC03

ziprasidone

40

mg

P

N05AE04

Change of DDDs:

INN/common name

Previous DDD

Unit

Adm.R

New DDD

Unit

Adm.R

ATC code

levofloxacin

0.25

g

O, P

0.5

g

O, P

J01MA12

to previous section to next section
 

Last updated: May 3, 2013